Entities / Company
GoodRx.
American prescription drug price tracking website and app
- Reports this week
- 0
- Active events
- 0
- Connections
- 59
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Citigroup, TD Cowen, Lazard Asset Management LLC, and Leerink Partners have issued positive analyst ratings and price target increases for GoodRx.Some support2 reports1 development inside
-
GoodRx stock traded on Nasdaq on August 1, 2026, while also being required to file sales disclosures with the SEC and holding a significant stake.Some support1 report
Gone quiet
No new reports in 90+ days-
A response to the punitive structural paradox observed within the U.S. healthcare system.Some support1 report1 development inside
-
GoodRx Companion offers affordable access to discounted services amid market failure in the U.S. healthcare ecosystem.Well supported4 reports
-
KeyBanc Capital Markets maintained an Overweight rating on GoodRx on June 24, 2025.Speculative1 report
-
Leerink partners maintained a bullish stance on GoodRx stock, citing benefits from tariffs and onshoring trends.Some support2 reports
-
Day One Biopharmaceuticals develops advanced medicines in the US and appoints Michael Vasconcelles as Head of R&D.Some support2 reports
-
GoodRx, Hims & Hers Health, and Omnicell are noted as operating within the healthcare technology segment.Some support2 reports
-
GoodRx, a company in the Medical Services industry, underperformed the S&P 500 this year.Some support2 reports
-
GoodRx stock underperformed the S&P 500 composite on August 7, 2025.Some support1 report
-
GoodRx reported that its revenue missed analyst estimates by 1.3% in August 2025.Some support1 report
-
Pharma partnerships are driving double-digit growth in the industry.Some support1 report
-
Powell's dovish signals suggest calmed markets, while a collaboration between GoodRx and Novo Nordisk aims to provide popular medications at a lower cost.Some support2 reports
-
GoodRx and Novo Nordisk partnered to offer discounts on diabetes and weight-loss drugs.Well supported5 reports
-
Ryan Sullivan was appointed Chief Marketing Officer at GoodRx in September 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around GoodRx this week
News at the entities that move GoodRx most-
Novo Nordisk OperationalBridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Moves GoodRx
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves GoodRx
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves GoodRx
-
Rite Aid OperationalRite Aid stores closed in Lockport, where Abbott operates. The closure is linked to David Adams and Kim Johnson, who are cousins.Moves GoodRx
-
Federal Trade Commission StructuralTrump is accused of destroying the structure involving the Department of Education, the Federal Trade Commission, and the East Wing.Moves GoodRx
-
Lazard Asset Management LLC TransactionalLazard Asset Management increased its stake in Dutch Bros Inc.Moves GoodRx
Connections
The 11 strongest of 59, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Wendy Barnes Structural
Wendy Barnes serves as the CEO and President of GoodRx, leading strategic and organizational changes.
-
Novo Nordisk Operational
GoodRx and Novo Nordisk collaborate on a partnership where GoodRx distributes Novo Nordisk's GLP-1 products and utilizes its platform for patient access.
-
FDA Structural
GoodRx provides access to medications that have received approval from the FDA.
-
Nasdaq Structural
GoodRx is a publicly listed company on the Nasdaq stock exchange.
-
Rite Aid Operational
Rite Aid's bankruptcy and operational changes negatively impact GoodRx's revenue outlook and market stability.
-
Federal Trade Commission Structural
The Federal Trade Commission has filed similar cases against GoodRx.
-
Leerink partners Mentioned together
Leerink Partners provides financial research and price targets for GoodRx stock.
-
Lazard Asset Management LLC Transactional
Lazard Asset Management lifted its investment position in GoodRx shares.
Show all 11 connections
-
Citigroup Mentioned together
Citigroup published market analysis regarding GoodRx, specifically raising its price target.
-
MarketBeat Mentioned together
MarketBeat reports financial ratings and price targets for GoodRx.
-
TD Cowen Mentioned together
TD Cowen provides financial analysis and target price ratings for GoodRx.
History
Events by the month they beganAugust 2026
2 eventsJune 2026
14 events- GoodRx CEO addressed the company's underperformance on August 13, 2025, as Rite Aid bankruptcy caused stores to be removed from networks. Inquiries focused on pharma manufacturer solutions growth.
- A response to the punitive structural paradox observed within the U.S. healthcare system.
- GoodRx Companion offers affordable access to discounted services amid market failure in the U.S. healthcare ecosystem.
- KeyBanc Capital Markets maintained an Overweight rating on GoodRx on June 24, 2025.
- Leerink partners maintained a bullish stance on GoodRx stock, citing benefits from tariffs and onshoring trends.
- Day One Biopharmaceuticals develops advanced medicines in the US and appoints Michael Vasconcelles as Head of R&D.
- GoodRx, Hims & Hers Health, and Omnicell are noted as operating within the healthcare technology segment.
- GoodRx, a company in the Medical Services industry, underperformed the S&P 500 this year.
- GoodRx stock underperformed the S&P 500 composite on August 7, 2025.
- GoodRx reported that its revenue missed analyst estimates by 1.3% in August 2025.
- Pharma partnerships are driving double-digit growth in the industry.
- Powell's dovish signals suggest calmed markets, while a collaboration between GoodRx and Novo Nordisk aims to provide popular medications at a lower cost.
- GoodRx and Novo Nordisk partnered to offer discounts on diabetes and weight-loss drugs.
- Ryan Sullivan was appointed Chief Marketing Officer at GoodRx in September 2025.